Skip to content
Triangle logo TriangleGet started
← CARMUSTINE: metastatic Hodgkin's Lymphoma

NCT02213913 · STUDY IN CONTEXT

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Draft scope assessment: unclear. Attached because the study's own record describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Number of patients with dose-limiting toxicity (DLT) defined as any grade 4 non-hemaotologic toxicity or any recurrent grade 3 non-hematologic toxicity despite optimal medical management

One patient in cohort 2 was non-evaluable for dose-limiting toxicity.

→

primary · POSTED

Time elapsed between treatment initiation and tumor progression or death from any cause, whichever occurs first.

Source null

→

primary · POSTED

The percentage of patients alive and progression-free at 1 year.

Source null

→

primary · POSTED

Percentage of patients alive and progression-free at 2 years.

Source null

→

secondary · POSTED

Percentage of patients alive and progression-free at 18 weeks.

Source null

→

secondary · POSTED

Partial response (PR) or complete response (CR) by computed tomography (CT) of positron emission tomography/CT and/or resolution of marrow-only involvement (if originally involved), according to the Revised Response Criteria for Malignant Lymphoma and Cheson et al.

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-carmustine-66189746
nct id
NCT02213913
trial label
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
applicability
unclear
applicability note
Attached because the study's own record describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
6
harms Count
4
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0000
    source section id
    NCT02213913-om-0000
    source outcome index
    0
    endpoint
    Dose-limiting Toxicity (Phase I)
    endpoint definition
    Number of patients with dose-limiting toxicity (DLT) defined as any grade 4 non-hemaotologic toxicity or any recurrent grade 3 non-hematologic toxicity despite optimal medical management
    time origin
    Up to 21 days
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    One patient in cohort 2 was non-evaluable for dose-limiting toxicity.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0001
    source section id
    NCT02213913-om-0001
    source outcome index
    1
    endpoint
    Progression-free Survival
    endpoint definition
    Time elapsed between treatment initiation and tumor progression or death from any cause, whichever occurs first.
    time origin
    Assessed up to 5 years
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0002
    source section id
    NCT02213913-om-0002
    source outcome index
    2
    endpoint
    Progression-free Survival at 1 Year
    endpoint definition
    The percentage of patients alive and progression-free at 1 year.
    time origin
    1 year
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0003
    source section id
    NCT02213913-om-0003
    source outcome index
    3
    endpoint
    Progression-free Survival at 2 Years
    endpoint definition
    Percentage of patients alive and progression-free at 2 years.
    time origin
    2 years
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0004
    source section id
    NCT02213913-om-0004
    source outcome index
    4
    endpoint
    Progression-free Survival at 18 Weeks
    endpoint definition
    Percentage of patients alive and progression-free at 18 weeks.
    time origin
    18 weeks
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0005
    source section id
    NCT02213913-om-0005
    source outcome index
    5
    endpoint
    Overall Response Rate
    endpoint definition
    Partial response (PR) or complete response (CR) by computed tomography (CT) of positron emission tomography/CT and/or resolution of marrow-only involvement (if originally involved), according to the Revised Response Criteria for Malignant Lymphoma and Cheson et al.
    time origin
    Up to 18 weeks
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Treatment (Lenalidomide 10 mg, DA-EPOCH-R)
    regimen
    Phase I Cohort 1: INDUCTION PHASE: Patients receive lenalidomide 10 mg PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months. lenalidomide: Given PO etoposide: Given IV prednisone: Given PO vincristine sulfate: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV rituximab: Given IV
    analyzed count
    3
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02213913-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0000
    arm key
    OG001
    arm label
    Treatment (Lenalidomide 15 mg, DA-EPOCH-R)
    regimen
    Phase I Cohort 2: INDUCTION PHASE: Patients receive lenalidomide 15 mg PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months. lenalidomide: Given PO etoposide: Given IV prednisone: Given PO vincristine sulfate: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV rituximab: Given IV
    analyzed count
    6
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02213913-om-0000#groups/OG001
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0000
    arm key
    OG002
    arm label
    Treatment (Lenalidomide 20 mg, DA-EPOCH-R)
    regimen
    Phase I Cohort 3: INDUCTION PHASE: Patients receive lenalidomide 20 mg PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months. lenalidomide: Given PO etoposide: Given IV prednisone: Given PO vincristine sulfate: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV rituximab: Given IV
    analyzed count
    5
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02213913-om-0000#groups/OG002
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Treatment (Lenalidomide 10 mg, DA-EPOCH-R)
    regimen
    Phase I Cohort 1: INDUCTION PHASE: Patients receive lenalidomide 10 mg PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months. lenalidomide: Given PO etoposide: Given IV prednisone: Given PO vincristine sulfate: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV rituximab: Given IV
    analyzed count
    3
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02213913-om-0001#groups/OG000
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0001
    arm key
    OG001
    arm label
    Treatment (Lenalidomide 15 mg, DA-EPOCH-R)
    regimen
    Phase I Cohort 2: INDUCTION PHASE: Patients receive lenalidomide 15 mg PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months. lenalidomide: Given PO etoposide: Given IV prednisone: Given PO vincristine sulfate: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV rituximab: Given IV
    analyzed count
    7
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02213913-om-0001#groups/OG001
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0001
    arm key
    OG002
    arm label
    Treatment (Lenalidomide 20 mg, DA-EPOCH-R)
    regimen
    Phase I Cohort 3: INDUCTION PHASE: Patients receive lenalidomide 20 mg PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months. lenalidomide: Given PO etoposide: Given IV prednisone: Given PO vincristine sulfate: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV rituximab: Given IV
    analyzed count
    5
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02213913-om-0001#groups/OG002
  7. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0001
    arm key
    OG003
    arm label
    Treatment (Lenalidomide 15 mg [MTD], DA-EPOCH-R)
    regimen
    Phase II Cohort 4: INDUCTION PHASE: Patients receive lenalidomide 15 mg PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months. lenalidomide: Given PO etoposide: Given IV prednisone: Given PO vincristine sulfate: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV rituximab: Given IV
    analyzed count
    40
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02213913-om-0001#groups/OG003
  8. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Treatment (Lenalidomide 10 mg, DA-EPOCH-R)
    regimen
    Phase I Cohort 1: INDUCTION PHASE: Patients receive lenalidomide 10 mg PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months. lenalidomide: Given PO etoposide: Given IV prednisone: Given PO vincristine sulfate: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV rituximab: Given IV
    analyzed count
    3
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02213913-om-0002#groups/OG000
  9. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0002
    arm key
    OG001
    arm label
    Treatment (Lenalidomide 15 mg, DA-EPOCH-R)
    regimen
    Phase I Cohort 2: INDUCTION PHASE: Patients receive lenalidomide 15 mg PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months. lenalidomide: Given PO etoposide: Given IV prednisone: Given PO vincristine sulfate: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV rituximab: Given IV
    analyzed count
    7
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02213913-om-0002#groups/OG001
  10. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0002
    arm key
    OG002
    arm label
    Treatment (Lenalidomide 20 mg, DA-EPOCH-R)
    regimen
    Phase I Cohort 3: INDUCTION PHASE: Patients receive lenalidomide 20 mg PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months. lenalidomide: Given PO etoposide: Given IV prednisone: Given PO vincristine sulfate: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV rituximab: Given IV
    analyzed count
    5
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02213913-om-0002#groups/OG002
  11. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0002
    arm key
    OG003
    arm label
    Treatment (Lenalidomide 15 mg [MTD], DA-EPOCH-R)
    regimen
    Phase II Cohort 4: INDUCTION PHASE: Patients receive lenalidomide 15 mg PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months. lenalidomide: Given PO etoposide: Given IV prednisone: Given PO vincristine sulfate: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV rituximab: Given IV
    analyzed count
    40
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02213913-om-0002#groups/OG003
  12. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Treatment (Lenalidomide 10 mg, DA-EPOCH-R)
    regimen
    Phase I Cohort 1: INDUCTION PHASE: Patients receive lenalidomide 10 mg PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months. lenalidomide: Given PO etoposide: Given IV prednisone: Given PO vincristine sulfate: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV rituximab: Given IV
    analyzed count
    3
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT02213913-om-0003#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    harm key
    EG000
    source section id
    NCT02213913-ae
    event group key
    EG000
    event group label
    Treatment (Lenalidomide 10 mg , DA-EPOCH-R)
    serious affected
    2
    serious at risk
    3
    other affected
    3
    other at risk
    3
    frequency threshold
    5
    collection period
    Up to 5 years.
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    harm key
    EG001
    source section id
    NCT02213913-ae
    event group key
    EG001
    event group label
    Treatment (Lenalidomide 15 mg, DA-EPOCH-R)
    serious affected
    2
    serious at risk
    7
    other affected
    7
    other at risk
    7
    frequency threshold
    5
    collection period
    Up to 5 years.
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    harm key
    EG002
    source section id
    NCT02213913-ae
    event group key
    EG002
    event group label
    Treatment (Lenalidomide 20 mg, DA-EPOCH-R)
    serious affected
    5
    serious at risk
    5
    other affected
    5
    other at risk
    5
    frequency threshold
    5
    collection period
    Up to 5 years.
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-carmustine-66189746
    nct id
    NCT02213913
    harm key
    EG003
    source section id
    NCT02213913-ae
    event group key
    EG003
    event group label
    Treatment (Lenalidomide 15 mg [MTD], DA-EPOCH-R)
    serious affected
    21
    serious at risk
    40
    other affected
    39
    other at risk
    40
    frequency threshold
    5
    collection period
    Up to 5 years.
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice